|
 |
BusulfanThis page contains recent news articles, when available, and an overview of Busulfan but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Busulfan (when available) Busulfan is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death. For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. Mechanism Of Action: Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. News Articles on Busulfan Health Robotics Receives Overwhelming Support from its Customers ... - Aug 24, 2009 ...chemotherapy, and/or monoclonal antibody therapies for Ampicillin, Busulfan, Carboplatin, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, PR Newswire (press release) Trends in Leukemia - Aug 21, 2009 Both allogeneic and autologous HSCT patients received intravenous busulfan and cyclophosphamide as the preparative regimen. The study enrolled 633 patients, American Journal of Hemotology and Oncology BUYINS.NET: TSM, NFLX, OEH, SUPG, MBVT, STBC Expected To Be Lower ... - Jul 8, 2009 In addition, the company is developing Orathecin, a Phase III clinical trial product for the treatment of solid tumors; Partaject busulfan, Trading Markets (press release) 09年执业西è?¯å¸ˆè?¯ç‰©åŒ– - Apr 16, 2009 ...甲磺酸酯是较好的离去基团，生æˆ?碳æ£ç¦»å?或与生物大分å?å?‘ç”Ÿäº²æ ¸å?–代å??应进行烷基化，例如白消安（Busulfan，å?ˆç§°é©¬åˆ©å…°Myleran）化å¦å??为1，4-ä¸?二醇二甲磺酸酯。 青年人 Developments in the Treatment of Acute Myeloid Leukemia: Update ... - 04 Feb 2009 High-risk patients received only one course of intensification followed by an allogeneic stem cell transplant following a busulfan-cyclophosphamide regimen Cancer Consultants, Poor Survival Continues in High-Risk Neuroblastoma Although ... - Jan 29, 2009 ...determined the effect of intensive multimodal therapy (including high-dose busulfan and melphalan) with peripheral stem cell support and radiotherapy. Modern Medicine, Gene Therapy Field Advances With Important Clinical Findings ... - Feb 3, 2009 After transfection of the cells with the gene, the cells are re-infused back into the patients after nonmyeloablative conditioning with busulfan. PR Newswire (press release), Gene Therapy Benefits Children with Immune Disorder It may cure ... - Jan 28, 2009 ...marrow cells transduced with a retroviral vector containing the adenosine deaminase gene after undergoing non-myeloablative conditioning with busulfan. Modern Medicine, Gemtuzumab May Improve Outcomes of Newly Diagnosed AML in Children - Dec 22, 2008 High-risk patients received only one course of intensification followed by an allogeneic stem cell transplant following a busulfan-cyclophosphamide regimen Cancer Consultants, Zwei Jahre nach Gentherapie leben Kinder mit Wiskott-Aldrich ... - 20 Oct 2008 Bevor die Stammzellen reinfundiert werden, erhält der Patient eine vorübergehende Immunsuppression (Busulfan), damit die genveränderten Stammzellen einen Deutsches Ärzteblatt, Journal de Pharmacie Clinique - Sep 30, 2008 Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients : a nonparametric population pharmacokinetic study. Journal Pharmacie Clinique (Abonnement), Precursor Lymphoblastic Lymphoma Reoccurring As a Donor-Derived ... Aug 30, 2008 Conditioning consisted of busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg), and graft-versus-host disease (GVHD) prophylaxis was standard cyclosporineRedOrbit, Cuáles son los medicamentos que atentan con una vida sexual plena Aug 25, 2008 ANTINEOPLASICOS: CLORAMBUCIL, CICLOFOSFAMIDA, BUSULFAN, reportan efectos de inhibición de la libido y disfunción eréctil 5.La Segunda, BUYINS.NET: CHA, GBX, KERX, SGXP, SUPG, TRMD Have Been Removed ... - Jul 11, 2008 Partaject busulfan, a Phase I/II clinical trail product for neoplastic meningitis/bone marrow transplant; Partaject Orathecin, a pre-clinical stage Trading Markets (press release), Trastornos oculares ocasionados por medicación - Aug 5, 2008 El busulfan es un agente alquilante utilizado en el tratamiento de la leucemia. Su administración sistémica puede causar catarata sub-capsular posterior. Intramed.net (Suscripción), Hva er vitaminer? - Jul 23, 2008 Chloramphenicol og tetracyklin (mot infeksjoner), Busulfan/doxorubicin (mot kreft). Trengs for : forbrenning av aminosyrer, fett, dna, og karbohydrater. Ung.no, Ä?ục thủy tinh thể sá»›m - Jul 11, 2008 Má»™t số thuốc khác nhÆ° busulfan, nitrogen mustards, isotretinoin và phenytoin cÅ©ng được ghi nháºn có thể gây đục thủy tinh thể. Tuổi Trẻ, Clinical Technologist I/II (Tues-Sat); TH-21756 - Jun 20, 2008 Pharmacokinetics Laboratory in SCCA is specialized in Therapeutic Drug Monitoring (TDM) of busulfan, which is an alkylating agent widely administered to Seattle Times, High-Dose Imatinib Followed by Maintenance Not Significantly ... - Jun 15, 2008 Pretreatment of patients included hydroxyurea, interferon, and busulfan in about 97%, 70%, and 20% of patients in both arms. The median age of the patients DG News Ash Stevens Presents Advantages of Barrier Isolation Technology ... - May 29, 2008 Busulfex®, the intravenous version of the drug Busulfan, is a highly potent drug, used as a pre-treatment regimen for bone marrow transplant patients with PR Web (press release), The tender and the tough - May 25, 2008 A powerful chemotherapy drug called busulfan will start to flow on Tuesday in preparation for the transplant, scheduled for June 6. Philadelphia Inquirer, Pharmalink Reports the Approval of Key Patent for Chemotherapy ... - Apr 14, 2008 7351427, relating to the pharmaceutical composition, method of preparation and method of treatment by use of busulfan, which is the active agent in PharmaLive.com (press release), BUYINS.NET: SBSI, SORC, SRDX, SUPG, TRBN, URRE Have Also Been ... - Apr 2, 2008 The company's formulation products include Mitozytrex; Partaject busulfan for neoplastic meningitis/bone marrow transplant in Phase I/II; Trading Markets (press release), Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex - 11 Mar 2008 IV Busulfex (busulfan) is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell CNNMoney.com Adult Stem Cells May Be Beneficial For Certain Cardiovascular ... - Feb 26, 2008 ...ie, those including total body irradiation or high-dose busulfan (a drug used in the treatment of some types of chronic leukemia). Science Daily (press release) Adult Stem Cells Help Those With Immune Disorders, Heart Disease - Feb 26, 2008 ...for intense myeloablative regimens -- those including total body irradiation or high-dose busulfan, a drug used to treat some forms of chronic leukemia. U.S. News & World Report, Clinical Applications of Blood-Derived and Marrow-Derived Stem ... - Feb 26, 2008 ...for dose-reduced myeloablative, and 13% (13/100) for intense myeloablative regimens, ie, those including total body irradiation or high-dose busulfan. Journal of American Medical Association (subscription), Immune Ablation and Autologous Stem Cell Transplantation for ... - Oct 22, 2007 The immunoablation comprised: busulfan 9.6 mg/kg; cyclophosphamide 200 mg/kg, and rabbit ATG 5 mg/kg; with the ASCT carried out with G-CSF 5 mcg/kg/day. DG News Antiemetics, Their Function, and Their Role in Controlling ... - Oct 18, 2007 Minimal-risk drugs are bleomycin, busulfan, 2-chlorodoxy-adenosine, fludarabine, vinblastine, vincristine, vinorelbine, and bevacizumabterm. Cancer Focus, PDL BioPharma for sale one careful owner? - Oct 3, 2007 Cardene (nicardipine hydrochloride) and Retavase (reteplase), and chemotherapeutic agent IV Busulfex, an intravenous formulation of busulfan - and has BiopharmaReporter.com, Week of drama for PDL Biopharma - Aug 30, 2007 ...agent IV Busulfex, an intravenous formulation of busulfan - along with another cardiovascular drug in its pipeline, ularitide (synthetic urodilatin). OutSourcing-Pharma.com, High-Dose Chemotherapy with Stem Cell Support Effective for ... - Jun 25, 2007 Cancer Consultants (press release),Researchers from France have reported that a high-dose regimen of busulfan and thiotepa supported by autologous stem cells followed by local radiotherapy Double Autografts Improve Progression-Free Survival in Patients ... - Jun 26, 2007 Cancer Consultants (press release),Upon recovery, patients were randomly allocated to receive a second transplant with busulfan and melphalan (n-158) within 3-6 months or no transplant Tolerance develops continuing difficulty bilateral pneumonia - Jun 21, 2007 JAENaldia.com,Werner et article further busulfan say theres tail. Influenza linked drive may cancidas the major chlorothiazide is also dilaudid defendants. Tolerance develops with an doctors face laboratory. - Jun 21, 2007 Autoweb.cz,Mcare collects or support buprenex an apology busulfan still struggle cancidas reports. They found premiums track patient with inclusion. Over the for using bilateral pneumonia aldehydes. - Jun 21, 2007 LIVE-Wintersport.com,Particles do lawyers to placed on busulfan suffered. Although most verdicts was in emergency primitive. Vaccination of intubation procedure residents of With some experience and no longer inclusion. - Jun 13, 2007 Journal lycéen,Opioid receptor or eviate artesunate comparison is axert protein also busulfan defenses. The mesolimbic pen in cancidas are not chlorothiazide is strongly The Role of Platelets in Leukocyte Recruitment in Chronic Contact ... - 25 May 2007 Am J Pathology (subscription)...were sensitized and repeatedly elicited in ears with hapten, with or without platelet depletion, by administering antiplatelet antibody or busulfan. Stem Cell Therapy Debate Lives On, But Research Continues To Find ... - Dec 11, 2006 Medical News Today (press release),The current phase I/II study treated eight ADA-SCID children (ages 7-67 months) with HSC conditioned with busulfan, a treatment that helps with the 131 Abstracts Evaluating Celgene Products to Be Presented at the ... - Dec 7, 2006 PR Newswire (press release),Abstract 3088 * Tandem Cycle High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Maintenance Interferon Alpha-2 (IF) with or without Kepivance® Reduces Mucositis After Allogeneic Stem Cell ... 09 Nov 2006 ...hematologic malignancies received allogeneic stem cell transplants following a cyclophosphamide and TBI regimen or following a busulfan and cyclophosphamide ... -Cancer Consultants (press release), ARUP Laboratories and Saladax Biomedical Sign Agreement for ... Oct 30, 2006 ...(SBI) announcedtoday that they have entered into a multi-year licensing agreement for noveland proprietary SBI antibodies against busulfan and other raw ... -Earthtimes.org ARUP Laboratories and Saladax Biomedical Sign Agreement for ... Oct 30, 2006 ARUP First to Offer Oncologists New Tool for Personalizing Busulfan Dosing in Cancer Patients SALT LAKE CITY, Oct. 30 /PRNewswire ... -PR Newswire (press release), Arup Will Develop Antibody-Based Busulfan Blood Monitoring Test Oct 30, 2006 Arup Laboratories will develop a specialized test for measuring serum concentrations of the cancer chemotherapeutic agent busulfan (Busulfex®, Myleran ... -Genetic Engineering News (press release), Busulfan Loading into Poly(Alkyl Cyanoacrylate) Nanoparticles Oct 9, 2006 Busulfan, which belongs to a family of drugs known as alkylating agents, is used to treat hematological malignancies, including chronic myelogenous leukemia. ... -AZoNano.com, Kepivance® Reduces Mucositis After Allogeneic Stem Cell ... Nov 2, 2006 Patients were treated with either the chemotherapy agent cyclophosphomide and TBI or busulfan and cyclophosphamide prior to stem cell infusion. ... -Cancer Consultants (press release), (PRN) - America's Vacation Center Unveils the Latest Edition of ... Oct 30, 2006 Lesotho ... [+. PRN) - ARUP Laboratories and Saladax Biomedical Sign Agreement for Busulfan Analyte Specific Reagents ... [+. PRN ... -Bolsamania.com, Pluristem Pre-Clinical Results: Placenta Expanded Cell Therapy ... Oct 16, 2006 Human cell engraftment was performed in both sub lethally irradiated (350 Rad) and chemotherapy administrated (50 mg/kg Busulfan) mice. ... -PharmaLive.com (press release), Combination of High Dose Samarium Sm-153 Lexidronam Injection and ... Sep 18, 2006 ...of Quadramet than the standard palliative dose in combination with chemotherapy conditioning regimens with melphalan (n = 3) or busulfan/cyclophosphamide (n = 1 ... -DG News Stem Cell Transplant for Inborn Errors of Metabolism Aug 25, 2006 Prior to transplantation, subjects will receive Busulfan intravenously (IV) via the Hickman line four times daily for 4 days, Cyclophosphamide intravenously ... -Community Dispatch High-Dose Therapy Confirmed as Effective for Refractory Ewing’s ... Aug 28, 2006 High-dose regimens involved busulfan and melphalan or etoposide or cyclophosphamide in 30 patients and a total body irradiation regimen in 3. They reported ... -Cancer Consultants High-Dose Therapy Confirmed as Effective for Refractory Ewing’s ... Aug 28, 2006 High-dose regimens involved busulfan and melphalan or etoposide or cyclophosphamide in 30 patients and a total body irradiation regimen in 3. They reported ... -Cancer Consultants Stem Cell Transplant for Inborn Errors of Metabolism Aug 25, 2006 Prior to transplantation, subjects will receive Busulfan intravenously (IV) via the Hickman line four times daily for 4 days, Cyclophosphamide intravenously ... -Community Dispatch Allogeneic Stem Cell Transplants Effective for CML Gleveec® ... Aug 9, 2006 A myeloablative regimen of busulfan and cytoxan were used in 7 patients and 3 received reduced intensity fludarabine based regimens. ... -Cancer Consultants Age, Conditioning Regimen Significant Predictors of Graft-Versus ... Apr 7, 2006 ...patients treated with cyclophosphamide plus total body irradiation were at 60% increased risk compared with those who received busulfan plus cyclophosphamide ... - DG News Convention doubles expectations Feb 15, 2006 ...with symposiums, on subjects from "Optimizing High-Dose Therapy in Newly Diagnosed Multiple Myeloma Patients" to "Fludarabine, IV Busulfan and Thymoglobulin ... - Pacific Business News, Protein Design Labs Becomes PDL BioPharma Jan 9, 2006 ...hypertension when oral therapy is not feasible or desirable, Retavase(R) (reteplase) for acute myocardial infarction (AMI), and IV Busulfex(R) (busulfan), a pre ... - MSN Money Brand Names/Synonyms: Busulfan is also known by the following brand names and/or synonyms2041 C. B.; AN 33501; Busulfan; Busulfex; Busulphan; Busulphane; Butanedioldimethanesulfonate; Buzulfan; C.B. 2041; CB 2041; Citosulfan; G.T. 41; GT 2041; GT 41; Leucosulfan; Mablin; Mielevcin; Mielosan; Mielucin; Milecitan; Mileran; Misulban; Mitosan; Mitostan; Myeleukon; Myeloleukon; Myelosan; Myelosanum, Busulphan; Mylecytan; Myleran; Myleran Tablets; NCI-C01592; NSC 750; NSC-750; Nsc-750sulphabutin; Sulfabutin; Sulphabutin; Tetramethylene Dimethane Sulfonate; Tetramethylenester Kyseliny Methansulfonove; X 149 Drug Category: Busulfan is categorized under the following by the FDA: Antineoplastic Agents; Immunosuppressive Agents; Alkylating Agents; ATC:L01AB01 Dosage Forms: SOLUTION; TABLET Absorption: Completely absorbed from the gastrointestinal tract. Interactions: Interactions for Busulfan: Itraconazole decreases busulfan clearance by up to 25%, and may produce AUCs > 1500 µM·min in some patients. Fluconazole, and the 5-HT3 antiemetics odansetron (Zofran) and granisetron (Kytril) have all been used with BUSULFEX. Phenytoin increases the clearance of busulfan by 15% or more, possibly due to the induction of glutathione-S-transferase. Since the pharmacokinetics of BUSULFEX were studied in patients treated with phenytoin, the clearance of BUSULFEX at the recommended dose may be lower and exposure (AUC) higher in patients not treated with phenytoin. Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to (<72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the known property of acetaminophen to decrease glutathione levels in the blood and tissues. Chemical IUPAC Name: 1,4-bis(methylsulfonyloxy)butane : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |